DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2062
INDEX
Polymyxins, 1538–1539
Polythiazide
pharmacology of, 688t
structure of, 688t
POMT. See Phenol-Omethyltransferase
(POMT)
PONARIS NASAL EMOLLIENT, 1153t
PONSTAN (mefenamic cid), 989
PONSTEL (mefenamic cid), 989
“Poor metabolizers,” 157
Population pharmacodynamics, 48–50
Population specific polymorphisms,
150
Porins, 1376
Porphyria cutanea tarda, antimalarials
for, 1819
Posaconazole, 1581–1582
pharmacokinetics of, 1874t
Positive allosteric modulators (PAMs),
220
Posterior chamber (ocular), 1774,
1775, 1776f
Postganglionic fibers, 174
Post-operative ileus, 1335
Postpartum hemorrhage, ergot
alkaloids in, 348–349
Potassium canrenoate
pharmacology of, 693t
structure of, 693t
Potassium channel(s), 59
ATP-sensitive, openers, as
antihypertensive agents,
788–781
and cardiac electrophysiology,
815–816, 816f
in neurotransmission, 182
openers, 1046
Potassium channel blockers, as
antiarrhythmics, 828
Potassium iodide, 1153t
Potassium-sparing diuretics. See
Diuretics, potassium-sparing
chemistry of, 690t
pharmacology of, 690t
structure of, 690t
therapeutic uses of, for heart failure,
791
Potency of drugs, 44–45
Potentiation, 77
Povidone iodine, 1153t
in ocular surgery, 1790
Poxvirus, 1818
PPAR. See Peroxisome proliferator
activator receptor(s) (PPAR)
PRADAXA (dabigatran etexilate),
865–866
Pralidoxime, 250
Pralidoxone hydrochloride, as antidote,
86t
Pramipexole
dosage of, 614t
pharmacokinetics of, 1874t
therapeutic uses of, for
parkinsonism, 614t
Pramlintide, 1265–1266
pharmacokinetics of, 1875t
Pramoxine hydrochloride, for pruritus,
1828t
Pranlukast, 942
Prasugrel, 870, 872
antiplatelet effects, site of action,
868f
structure of, 869f
PRAVACHOL (pravastatin), 897
Pravastatin, 893, 894
absorption, fate, and excretion of,
896
chemistry of, 894
dosage of, required to achieve
reduction in LDL-C, 895t
pharmacokinetics of, 1875t
polymorphisms and response to,
160t, 161t
SLC transporters and, 102t
structure of, 893f
therapeutic uses of, 897
in children, 898
Prazepam
administration and uses of, 466t
structure of, 459t
Praziquantel, 1456–1458
pharmacokinetics of, 1875t
Prazosin, 305–307, 306f
adrenergic receptors and, 206t
as antihypertensive agent, 774t,
779–780
pharmacological properties of,
305–307
PRECEF (ceforanide), 1494t
Preclinical research, 6–7
Pre-clinical trials, 142
Precocious puberty, 1120–1121
Prednisolone
pharmacokinetics of, 1876t
relative potencies and equivalent
doses of, 1216t
Prednisone, 1668t–1670t
arrhythmias caused by, 832
in cancer chemotherapy, 1755
oral, dosage and administration of,
1809
pharmacokinetics of, 1876t
Prednisone (Cont.):
relative potencies and equivalent
doses of, 1216t
therapeutic uses of, dermatologic,
1809
Pre-eclampsia, 1847
Pre-emptive antimicrobial therapy,
1374–1375
Pregabalin, 599
pharmacokinetics of, 1877t
Preganglionic fibers, 174
Pregnancy
antiepileptics in, 605–606
benzimidazoles in, 1452–1453
eicosanoids and, 948
gastroesophageal reflux disease,
1319
hypothyroidism in, 1144
inflammatory bowel disease in,
1360–1361
lithium use in, 449–450
placental transfer of drugs and, 25
salicylates and, 981
statins and, 897
termination of, drugs for, 1837
thyrotoxicosis in, 1150
Pregnancy categories, for drugs, 1846,
1846t
Pregnancy-induced hypertension, 1847
Pregnane X receptor (PXR), 97, 140,
140t, 141, 141f
Prehypertension, diagnostic criteria
for, in adults, 773t
Prejunctional sites, 189
Prekallikrein, 929
Preload, 756
pharmacological modification, 756
PREMARIN (conjugated estrogens),
1839t
PREMARIN (conjugated estrogens
cream), 1839t
Premature ventricular beat, ECG of,
825f
Prenalterol, 279t
PREPIDIL (dinoprostone), 1849
Prescription, as commodity,
1882–1883
Prescription Drug User Fee Act
(PDUFA), 9
Prescription pad, 1881–1882
Prescription writing
abbreviations in, 1880–1881
authority for, 1880
compliance and, 1881–1882
confusion in, 1880–1881
current practice, 1879–1880